Oncology's big confab, ASCO, will spotlight the promise of immuno-oncology combination treatments. But along with the excitement born from innovation will come the inevitable questions about cost.
from Forbes Real Time https://www.forbes.com/sites/arleneweintraub/2018/06/01/asco-preview-are-combo-treatments-with-cancer-killing-viruses-worth-the-cost/
via IFTTT
No comments:
Post a Comment